Publication date: Feb 03, 2025
Pediatric oncology and hematopoietic stem cell transplant (HSCT) patients may fail to mount an appropriate immune response to COVID-19 vaccinations. The immunologic response to initial SARS-CoV-2 vaccination was studied in 93 pediatric patients with hematologic malignancy, solid tumors, or post-HSCT. The majority of patients who were not receiving chemotherapy showed a positive humoral and cell-mediated response to COVID-19 vaccination. In contrast, variable responses to vaccination were seen in patients receiving chemotherapy. Patients with a normal lymphocyte count showed higher rates of seroconversion than their lymphocytopenic counterparts. This report details pediatric oncology and HSCT patients’ immunologic responses to COVID-19 vaccination during all phases of treatment.
| Concepts | Keywords |
|---|---|
| Chemotherapy | |
| Lymphocytopenic | |
| Pediatric | |
| Vaccinations |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | cell |
| disease | IDO | immune response |
| disease | MESH | COVID-19 |
| disease | MESH | hematologic malignancy |
| disease | MESH | tumors |
| disease | MESH | seroconversion |
| disease | IDO | assay |